Latest News Highlights

Suspension of registration of products from the drug register

Thursday, 11th October 2018

Background

NDA is mandated to ensure that the population of Uganda has access to safe, effective and quality drugs

We received market complaints on quality of different pharmaceutical products. Some of the complaints were related to the occurrence of serious adverse events whereas other products had critical quality defects posing a risk to public health. Further investigations revealed that the manufacturing facilities of some of these drugs did not comply with Good Manufacturing Practices (GMP) requirements.

The National Drug Authority Board then decided to suspend and recall All Parenteral (Injectable) products manufactured by the facilities which were found to operate at unacceptable levels of GMP requirements. These include;

   No
   Manufacturer
   Name of Drug
   Generic Name of Drug
   1

JIANGSU PENGYAO PHARMACEUTICALS CO. LTD -NO. 10 CHAQUAN ROAD YIXING CITY JIANGSU PROVINCE, CHINA

R-ETHER
GMYCIN-80
FALCIMAX-600
ARTEMETHER INJECTION
QUININE DIHYDROCHLORIDE INJECTION
DICLOMAX-75


ARTEMETHER 80MG/ML
GENTAMYCIN SULPHATE 80MG/2ML
QUININE DIHYDROCHLORIDE 600MG/2ML
ARTEMETHER 80MG/ML
QUININE DIHYDROCHLORIDE 600MG/2ML
DICLOFENAC SODIUM 75MG/ML

   2

ANHUI CHENGSHI MEDICINE MANUFACTURE CO. LTD-INDUSTRIAL AREA, BENGBU CITY, ANHUI PROVINCE, CHINA

GENTAMYCIN INJECTION
ARTEMETHER INJECTION
VITAMIN B INJECTION
DICLOFENAC SODIUM

GENTAMYCIN 80MG/2ML
ARTEMETHER 80MG/ML
VIT B1 + VIT B2 + VIT B6 + NICOTINAMIDE + CALCIUM
DEXTROPANTOTHENATE
DICLOFENAC 75MG/3ML

   3

SHANDONG XIER KANGTAI PHARMACEUTICAL CO. LTD-PRIVATE ECONOMY ZONE, YANZHOU DISTRICT, SHANDONG, CHINA PR


CELLTRIAXON
EXPEN
PROCILIN


CEFTRIAXONE 1GM
BENZYLPENICILLIN 1MU
FORTIFIED PROCAINE BENZYLPENICILLIN 4MU

NOTE: The names of drugs in the table above apply only to those drugs manufactured by the suspended manufacturing facilities.

Advise to Health workers.

1.    Do not purchase any Injectable products manufactured by the companies in the table above. The license holders of these products have been instructed to recall the affected products and halt any importation.

2.    Quarantine and return all of the affected products to their suppliers

3.    To Report to NDA any adverse drugs reactions associated with similar products or any other product defects. Reports can be sent to any NDA office or by email to druginfo@nda.or.ug or calling 0414-255665 or by sending a message on WhatsApp to 0791415555

Thank you for your continued cooperation
Helen Byomire Ndagije

DIRECTOR PRODUCT SAFETY

Copy:  Director Health Services, Clinical Services, Ministry of Health

            Director Product Assessment and Registration

            Director, Inspectorate and Enforcement